ValiRx Plc (LON:VAL) Rating Reiterated by Beaufort Securities

Beaufort Securities restated their speculative buy rating on shares of ValiRx Plc (LON:VAL) in a research note released on Friday, October 13th. They currently have a GBX 6.50 ($0.09) price target on the stock.

Shares of ValiRx Plc (VAL) opened at 1.025 on Friday. ValiRx Plc has a one year low of GBX 0.94 and a one year high of GBX 7.65. The stock’s market cap is GBX 1.47 million. The company has a 50-day moving average of GBX 1.26 and a 200 day moving average of GBX 1.90.

WARNING: This report was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://ledgergazette.com/2017/10/22/valirx-plcs-val-speculative-buy-rating-reaffirmed-at-beaufort-securities.html.

ValiRx Plc Company Profile

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment o

Shares of ValiRx Plc (VAL) opened at 1.025 on Friday. ValiRx Plc has a one year low of GBX 0.94 and a one year high of GBX 7.65. The stock’s market cap is GBX 1.47 million. The company has a 50-day moving average of GBX 1.26 and a 200 day moving average of GBX 1.90.

WARNING: This report was reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are viewing this report on another domain, it was illegally copied and reposted in violation of US & international trademark & copyright legislation. The legal version of this report can be accessed at https://ledgergazette.com/2017/10/22/valirx-plcs-val-speculative-buy-rating-reaffirmed-at-beaufort-securities.html.

ValiRx Plc Company Profile

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply